MUC17 and cancer: We further explored the potential signaling pathways affected by the downregulation of MUC17 in drug-resistant cells, the activation of the NF-κB signaling pathway caused by gefitinib/osimertinib resistance may aggravate inflammation and the progression of malignant tumors.